The Research Division of BioTelemetry

BioTelemetry Research, formerly Cardiocore, is an industry leader in clinical trials testing services, monitoring, data, and scientific consulting. Our comprehensive offerings provide global clients with world-leading technology, data management, and consulting services, streamlining the clinical trials process, and ensuring optimal research performance.

Every day, BioTelemetry Research’s global clinical trials services team meets the demands of Phase I–IV studies for the world’s largest pharmaceutical organizations, specialty pharmaceutical firms, emerging biotechnology companies, and medical device manufacturers. Providing a full range of centralized clinical trials testing modalities for both safety and endpoint evaluation, our core offerings include:

Comprehensive Testing Services for Clinical Trials

Today as BioTelemetry Research, we are a member of the world’s largest cardiac data network — processing over 2 billion heartbeats a day, while supporting more than 20,000 sites and 30,000 devices monthly, as well as monitoring over 500,000 patients a year. In addition to industry-leading global cardiovascular monitoring, we have now expanded our clinical trial services in two important areas: advanced imaging services for oncology, neurologic, cardiac, and musculoskeletal imaging, and a global alliance for respiratory testing and clinical trials expertise.


May 11, 2016

BioTelemetry, Inc. Announces the Completion of Its Acquisition of VirtualScopics, Inc.

MALVERN, Pa., May 11, 2016 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that it has completed its acquisition of VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions. The […]

Read More More News


May 13, 2015

Blood Pressure Evaluation During Early Phase Trials

Daniel B. Goodman, MD, Michael A. Weber, MD; 3 Nov 2014

More attention is being paid to blood pressure (BP) effects in new chemical entities under development for non-hypertension indications, especially when these are not anticipated and not thoroughly defined during drug development.

More Publications



Jun 3-7, 2016


Chicago, IL
Booth #19024

More Events